FibroBiologics CSO buys 298K shares, warrants
FibroBiologics’ chief scientific officer bought stock and received matching long-dated warrants in a private placement, increasing his direct ownership.
Rhea-AI Filing Summary
FibroBiologics, Inc. (FBLG) reported that Chief Scientific Officer Hamid Khoja acquired 298,508 shares of common stock on September 15, 2026 at $1.675 per share in a private placement, together with warrants to purchase up to 298,508 additional shares at an exercise price of $1.55 per share, exercisable until September 15, 2031. Following these awards, he holds 301,571 shares of common stock directly, along with 298,508 warrants.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
Grant/Award: 597,016 shares
Grant/Award
2 txns
Insider
Khoja Hamid
Role
Chief Scientific Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Warrant (Right to Buy) F1, F2, F3 | 298,508 | -- | -- |
| Grant/Award | Common Stock F1, F2 | 298,508 | $1.675 | $500K |
Holdings After Transaction:
Warrant (Right to Buy) — 298,508 contracts (Direct);
Common Stock — 301,571 shares (Direct)
Footnotes (3)
- F1. On September 15, 2026, the reporting person entered into a securities purchase agreement with FibroBiologics, Inc. (the "Company") to purchase 298,508 shares of the Company's common stock, par value $0.00001 per share (the "Common Stock"), and accompanying warrants to purchase up to 298,508 shares of Common Stock (the "Warrants"), in a private placement (the "Offering").
- F2. Each share of Common Stock and accompanying Warrant were issued at a combined purchase price of $1.675.
- F3. The warrants are exercisable at any time until they expire.
Key Figures
Common stock acquired: 298,508 shares
Acquisition price per share plus warrant: $1.675
Warrants acquired: 298,508 warrants
+4 more
7 metrics
Common stock acquired
298,508 shares
Shares of FibroBiologics common stock acquired on September 15, 2026
Acquisition price per share plus warrant
$1.675
Combined purchase price for each share of common stock and accompanying warrant
Warrants acquired
298,508 warrants
Warrants to purchase common stock acquired in the private placement
Warrant exercise price
$1.55 per share
Exercise price for the common stock underlying the warrants
Warrant expiration date
September 15, 2031
Date the reported warrants expire
Common shares held after transaction
301,571 shares
Direct FibroBiologics common stock holdings following the acquisition
Reporting person role
Chief Scientific Officer
Officer title of reporting person Hamid Khoja at FibroBiologics
Key Terms
securities purchase agreement, private placement, warrants
3 terms
securities purchase agreement financial
"the reporting person entered into a securities purchase agreement with FibroBiologics, Inc."
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
private placement financial
"shares of Common Stock and Warrants... in a private placement (the "Offering")"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
warrants financial
"accompanying warrants to purchase up to 298,508 shares of Common Stock"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did FBLG’s chief scientific officer report on this Form 4?
Hamid Khoja reported acquiring 298,508 shares of FibroBiologics common stock and 298,508 warrants to buy additional shares on September 15, 2026 under a securities purchase agreement in a private placement.
At what prices were the FBLG securities acquired in this filing?
Each share of FibroBiologics common stock and accompanying warrant was issued at a combined purchase price of $1.675. The warrants have an exercise price of $1.55 per share for the underlying common stock.
What are the key terms of the FBLG warrants reported in this Form 4?
The reported warrants permit purchase of up to 298,508 FibroBiologics common shares at an exercise price of $1.55 per share and are exercisable at any time until they expire on September 15, 2031.
Was this FBLG insider transaction under a Rule 10b5-1 trading plan?
The filing indicates no Rule 10b5-1 plan for these transactions, as the relevant checkbox is not marked and the footnotes describe a negotiated securities purchase agreement and private placement instead.
AI-generated analysis. How Rhea-AI works. Not financial advice.
